find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
19
Clinical Trials
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06966700 / MK2870-032
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer
Learn More
Breast Cancer Clinical Trials
Unspecified
Enrolling
nct/study# NCT05570253 / MSK22-074
Phase 2 Randomized Control Trial of Evexomostat (SDX-7320) in Combination with Eribulin for Patients with Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT05879926 / NRG-BR009
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Learn More
Breast Cancer Clinical Trials
N/A
Enrolling
nct/study# NCT07038785 / PINK
A Double Blind Observational Study to Validate the SpotitEarly Test for the Detection of Breast Cancer
Learn More
Breast Cancer Clinical Trials
Phase II/III
Enrolling
nct/study# NCT05256745 / RAGE-IIT
RAGE inhibition to decrease cancer therapy related cardio toxicity in women with early breast cancer
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06982521 / RLY-2608-102
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.